Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases
Existence and cause of thyroid stunning was controversially discussed for decades but the underlying mechanism remains unclear. Numerous studies describe thyroid stunning in radioiodine-131 therapy (RIT) of differentiated thyroid carcinoma. However, there are no studies evaluating thyroid stunning in benign thyroid diseases caused by the radioiodine uptake test (RIUT). Therefore, the influence of pre-therapeutic tracer radiation dose on therapeutic iodine-131 uptake was evaluated retrospectively.
A total of 914 RIT patients were included. Exclusion criteria were anti-thyroid drugs, pre- and/or intra-therapeutic effective half-lives (EHL) beyond 8.04 days and externally performed RIUT or 24 h RIUT. All patients received RIUT 1 week before RIT. Thyroid volume was estimated via ultrasound. Tracer radiation dose to the thyroid was calculated retrospectively. The dependence of changes in the pre-therapeutic to the therapeutic extrapolated-maximum-131I-uptake (EMU) from the dose in RIUT was evaluated statistically.
EMU in RIUT ranged from 0.10 to 0.82 (median: 0.35) and EMU in RIT ranged from 0.10 to 0.74 (median: 0.33). Averaged over the whole cohort the therapeutic EMU decreased significantly (2.3% per Gray intra-thyroidal tracer radiation dose). A disease-specific evaluation showed dose-dependent thyroid stunning from 1.2% per Gray in solitary toxic nodules (n = 327) to 21% per Gray in goiters (n = 135) which was significant for the subgroups of disseminated autonomies (n = 114), multifocal autonomies (n = 178) and goiters (p < 0.05) but not for Graves’ diseases (n = 160) and solitary toxic nodules (p > 0.05).
The presented data indicate for the first time a significant dependence of pre-therapeutic radiation dose on thyroid stunning in goiter and disseminated and multifocal autonomy. To achieve the desired intra-thyroidal radiation dose, RIT activity should be adapted depending on the dose in RIUT.
KeywordsRadioiodine therapy Radioiodine uptake test Thyroid stunning Benign thyroid disease Thyroid
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study. This article does not contain any studies with animals performed by any of the authors.
- 2.M. Freesmeyer, F. Gühne, C. Kühnel, T. Opfermann, T. Winkens, A. Werner Determination of effective half-life of 131I in patients with differentiated thyroid carcinoma: comparison of cystatin C and creatinine-based estimation of renal function. Endocrine (2018). https://doi.org/10.1007/s12020-018-1800-4
- 4.E. Bell, F. Grünwald. Radiojodtherapie bei Benignen und Malignen Schilddrüsenerkrankungen (Springer-Verlag Berlin Heidelberg, New York, 1999).Google Scholar
- 5.R.W. Rawson, J.E. Rall, W. Peacock, Limitations in the treatment of cancer of the thyroid with radioactive iodine. Trans. Assoc. Am. Physicians 64, 179–198 (1951)Google Scholar
- 6.W. Brenner, Is thyroid stunning a real phenomenon or just fiction? J. Nucl. Med. 43, 835–836 (2002)Google Scholar
- 10.S.P. Cholewinski, K.S. Yoo, P.S. Klieger, R.E. O’Mara, Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J. Nucl. Med. 41, 1198–1202 (2000)Google Scholar
- 11.M. Filesi, M. Colandrea, T. Montesano, R. D’Apollo, G. Ronga, Thyroid stunning in clinical practice: is it a real problem? Minerva Endocrinol. 34, 29–36 (2009)Google Scholar
- 12.J.M. Woolfenden, Thyroid stunning revisited. J. Nucl. Med. 47, 1403–1404 (2006)Google Scholar
- 15.M. Lassmann, M. Luster, H. Hänscheid, C. Reiners, Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J. Nucl. Med. 45, 619–625 (2004)Google Scholar
- 17.J.P. Muratet, A. Daver, J.F. Minier, F. Larra, Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J. Nucl. Med. 39, 1546–1550 (1998)Google Scholar
- 18.P. Postgård, J. Himmelman, U. Lindencrona, N. Bhogal, D. Wiberg, G. Berg, S. Jansson, E. Nyström, E. Forssell-Aronsson, M. Nilsson, Stunning of iodide transport by 131I irradiation in cultured thyroid epithelial cells. J. Nucl. Med. 43, 828–834 (2002)Google Scholar
- 20.B. Meller, E. Gaspas, W. Deisting, B. Czarnocka, M. Baehre, B.E. Wenzel, Decreased radioiodine uptake of FRTL-5 cells after 131I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway. Eur. J. Nucl. Med. Mol. Imaging 35, 1204–1212 (2008)CrossRefGoogle Scholar
- 21.C. Lundh, M.M. Nordén, M. Nilsson, E. Forssell-Aronsson, Reduced iodine transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J. Nucl. Med. 48, 481–486 (2007)Google Scholar
- 22.C. Lundh, U. Lindencrona, P. Postgård, T. Carlsson, M. Nilsson, E. Forssell-Aronsson, Radiation-induced thyroid stunning: differential effects of 123I, 131I, 99mTc and 211At on iodide transport and NIS mRNA expression in cultured thyroid cells. J. Nucl. Med. 50, 1161–1167 (2009)CrossRefGoogle Scholar
- 24.J.C. Sisson, A.M. Avram, S.A. Lawson, P.G. Gauger, G.M. Doherty, The so-called stunning of thyroid tissue. J. Nucl. Med. 47, 1406–1412 (2006)Google Scholar
- 25.Y. Yin, Q. Mao, S. Chen, N. Li, X. Li, Y. Li, A quantitative study about thyroid stunning after diagnostic whole-body scanning with 74 MBq 131I in patients with differentiated thyroid carcinoma. Q. J. Nucl. Med. Mol. Imaging 59, 455–461 (2015)Google Scholar
- 28.E. Wudel, K. Koppenhagen, The stunned thyroid? Veränderte Radiojodkinetik der NACH-THERAPIE bei benignen Schilddrüsenerkrankungen. Nuklearmedizin 34, A166 (1995). (Abstract)Google Scholar
- 32.F.A. Leger, M. Izembart, F. Dagousset, L. Barritault, G. Baillet, A. Chevalier, J. Clerc, Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur. J. Nucl. Med. 25, 242–246 (1998)CrossRefGoogle Scholar
- 37.H.W. Yeung, J.L. Humm, S.M. Larson, Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J. Nucl. Med. 41, 1082–1085 (2000)Google Scholar
- 40.T. Bajén, S. Mañé, A. Muñoz, J.R. García, Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J. Nucl. Med. 41, 2038–2042 (2000)Google Scholar
- 43.N.A. Damle, C. Bal, S. Ballal, Stunning in post (131)I therapy scans after low-dose (131)I diagnostic whole body scans with differentiated thyroid cancer in the Indian patient population: critical importance of interval between the two scans. Indian J. Endocrinol. Metab. 16, 477–478 (2012)CrossRefGoogle Scholar
- 48.A. Siddiqi, R.R. Foley, K.E. Britton, A. Sibtain, P.N. Plowman, A.B. Grossman, J.P. Monson, G.M. Besser, The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin. Endocrinol. (Oxf.). 55, 515–521 (2001)CrossRefGoogle Scholar
- 49.M. Ruhlmann, W. Sonnenschein, J. Nagarajah, I. Binse, K. Herrmann, W. Jentzen, Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities. Nucl. Med. Commun. 39, 457–464 (2018)CrossRefGoogle Scholar
- 51.K. Watanabe, T. Igarashi, H. Ashida, S. Ogiwara, T. Ohta, M. Uchiyama, H. Ojiri. Diagnostic value of ultrasound and Tl-201/Tc-99m dual scintigraphy in differentiating between benign and malignant thyroid nodules. Endocrine (2018). https://doi.org/10.1007/s12020-018-1768-0